Last updated on November 2018

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer


Brief description of study

The purpose of this study is to determine whether Nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Clinical Study Identifier: NCT02743494

Contact Investigators or Research Sites near you

Start Over

Crystal Denlinger, Site 0048

Fox Chase Cancer Center
Philadelphia, PA United States
1.35miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.